Payers Beware: J&J, Merck Try To Facilitate Use Of Their HCV Agents With Gilead’s Sovaldi
This article was originally published in The Pink Sheet Daily
Executive Summary
Janssen and Merck are pursuing clinical development strategies that may make reimbursement less challenging for co-administration of their HCV drugs with Sovaldi. Janssen has filed an sNDA for co-administration of its Olysio with Sovaldi in fibrotic patients, while Merck is beginning a combination trial looking at a four-week duration of therapy.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.